BSG BioNewsLetter 09#2002 - BioSeeker Group's analysis and products eNewsletter
URL: http://www.bioseeker.com http://www.bsg-online.biz
-- CONTENTS --
1) New Report: 'Molecular Approaches towards HCV Therapy - The Complete Guide'
2) BioSeeker launches BioNewsletter Pro
3) Recently Published Reports
4) Conference Opportunity - BioBusiness 2003
5) BioSeeker in Strategic Use of SkyMinder
6) Coming reports: Osteoporosis Therapy / Colon Cancer / Immunotherapy Strategies
7) Subscription
8) BioSeeker Online Store
====================================================================
1) MOLECULAR APPROACHES TO HCV THERAPY - THE COMPLETE GUIDE
- A new report from BioSeeker Group
It is obvious that pegylated interferons in combination with nucleoside analogs such as ribavirin will dominate the HCV market for the next few years. Despite this, the interest in developing novel HCV therapies is still strong and the enthusiasm for specifically targeted HCV drugs such as protease inhibitors is increasing. The understanding of hepatitis C at a molecular level has also opened the door for more targeted development of a prophylactic or therapeutic HCV vaccine.
This 300 page report is a comprehensive document providing the reader with an extensive amount of information. We describe and assess the ongoing struggle for improved and novel HCV drug discovery technologies as well as the whole range of molecular approaches towards new HCV therapy. These strategies include immuno-modulating substances, protease inhibitors, vaccines, polymerase inhibitors, nucleoside analogues, ribozymes, iminoglucosidase inhibitors, caspase inhibitors, antibodies, and many more. Other therapeutic or prophylactic approaches such as hyperthermia or plasma inactivation are discussed. The various approaches are analyzed according to the opportunities in the short, mid-range and long-term market development; and how the return on investment can be maximized bearing this view in mind.
For your convenience BioSeeker Group has included extensive appendices with recent patents, detailed information regarding clinical trials and collaborations, and the current collaboration clusters. Activities from a total of 129 companies are described.
Previously BioSeeker Group has published two Highlight Reports focusing on HCV ('Fierce Competition for a Shrinking HCV Market' in Oct. 2002 and 'Future HCV Drug Discovery Technologies' in Nov). All of the information in these reports is also included in 'The Complete Guide'. These reports both serve well as briefer alternatives focusing on specific topics. All previous and future customers of these highlight reports are entitled to a discount of the full report cost when purchasing 'The Complete Guide'.
For more information about BioSeeker Group's HCV reports, please visit http://hcv-therapeutics.info
====================================================================
2) BIOSEEKER LAUNCHES BIONEWSLETTER PRO
- Subsrcibe Now and Receive a Report for Free!
As a subscriber of the BioNewsletter Pro you will receive 26 issues per year of in-depth, analytical articles on hot topics in the biotech and pharma industries. We identify different areas of special interest and provide you with updated information including interviews with key people in the field.
Further, when signing up as a subscriber you will receive one of the following BioSeeker reports, entirely free of charge:
- Pan-European Investors in the Biotechnology Industry
- Swedish Investors in Biotechnology
- Swedish Biotechnology Industry
- In Depth Financial Report on the Swedish Biopharma Branch 2002
- R&D in Swedish Biopharma Companies 2002
From time to time BioSeeker Group will also make certain offers available to BioNewsletter Pro subscribers. For more information, please visit www.bioseeker.com.
====================================================================
3) RECENTLY PUBLISHED BIOSEEKER REPORTS
- Ion Channels as Therapeutic Targets for Multiple Diseases (released Nov, 2002)
http://www.bioseeker.com/index.asp?report=ionchanneltargets
- New Targets and Drug Discovery Platforms in Antifungal R&D (released Nov, 2002)
http://www.bioseeker.com/index.asp?report=antifungal2
- The Next Generation Antifungals: Triazoles vs. Peptides
http://www.bioseeker.com/index.asp?report=antifungal (released Oct, 2002)
- Swedish Biopharma Industry - The Next Wave (released Sept, 2002)
http://www.swedishpharma.info
- Ion Channel Assays in the Drug Discovery Process (released June, 2002)
http://www.ion-channels-in-drug-discovery.info
- Commercializing on Tumor Antigens: Analytical Perspectives (released Feb, 2002)
http://www.commercializing-tumor-antigens.info
====================================================================
4) CONFERENCE OPPORTUNITY - BioBusiness 2003
BioBusiness 2003 is the premier bio-partnering event for biotech and pharma business development and licensing executives. At this senior-levelinternational event you won't have to trawl through your 200 fellow attendees to find fellow business development and licensing professionals as these are the only biotech and pharma representatives coming! So instead of wasting your time looking for them, you can concentrate on discussing strategies with them in interactive roundtable groups or formulating future plans with them in private one-to-one meetings. Plus you can learn from the best! Hear from 16 leading pharmaceuticals and 15 world class biotechs, such as Novartis, F. Hoffman La Roche, Boehringer Ingelheim, Aventis, Genentech, Genzyme and Vertex Pharmaceuticals, who will tell you what they are currently looking for in business partners and how they see alliance and partnering strategies developing in the next five years. Book your place now!
For more information, please visit http://www.wbr.co.uk/biobusiness2003/index.html or contact Colin Chapman (colin2||wbr.co.uk)
====================================================================
5) BIOSEEKER GROUP IN STRATEGIC USE OF SKYMINDER
BioSeeker Group's intelligence is now further enhanced by the strategic use of SkyMinder, the ideal tool for business information from the highest quality information sources all over the world, all accessible on-line and in real time.
To give the BSG BioNewsletter readers the very best, we have asked SkyMinder to highlight their capabilities in providing world wide company information on the biotechnology and pharmaceutical industry through our website www.bioseeker.com.
====================================================================
6) COMING REPORTS
- Winning the Osteoporosis Therapy Race
Sales of osteoporosis drugs in totaled $3.4 billion in 2000, and are expected to reach $6.5 billion by 2005. A new class of osteoporosis therapies, designed to build bone mass in contrast to currently available anti-osteoporosis medicines are presently under study. These anabolic therapies consist of parathyroid hormone (Forteo and ALX-11) or fluoride to stimulate bone formation, but their safety and efficacy remain to be established. The first of these drugs to reach the market will probably be Forteo, known generically as teriparatide (recombinant parathyroid hormone).
Please contact us for more information about this report (bioinfo*_*bioseeker.com). For further reading about osteoporosis, please visit our free analytical article on this topic (http://www.bioseeker.com/docs/topics/topic_osteoporosis.asp)
- Advancements in Colon Cancer Therapeutics
In this report, BioSeeker has indentified a number of emerging strategies for colon cancer therapeutics. The report discusses and assesses early and late stage projects in this area. BioSeeker focuses on the areas regarded as the "hottest leads" at the moment. The core focus is on angiogenesis, reverse DNA methylation and colon specific suppressor genes. We also discuss monoclonal antibodies, tumor antigens, signal pathways and apoptosis. Therapies that have been specially studied include, immunotherapy, gene therapy and antisense therapy. Company information is also provided for partnership and drug clinical status in colorectal cancer for the main players in the field.
For more information about this report, please contact us at bioinfo ~~ bioseeker.com
- A Shift in Cancer Immunotherapy Strategies?
Immunotherapy has for some time been tried as a breakthrough approach for cancer treatment, but failed. More simple protocols are now changed for more sophisticated ones, and even now novel solutions are emerging. Recent insights into the cells, molecules and signalling pathways that regulate immune responsiveness are providing new approaches for immunotherapy. And new insights have suggested that it might be beneficial to begin tumour immunotherapy soon after the completion of chemotherapy to induce effective homeostatic T-cell proliferation.
This report evaluates the latest advancements in cancer immunotherapy as well as describes key company activities. BioSeeker Group is monitoring a lagre number of companies working in this field for the possibility of generating highly updated analysis. For more information about this report, please contact us at bioinfo ~ bioseeker.com
====================================================================
7) SUBSCRIPTION
To continue to stay tuned with coming editions of BioSeeker Groups free BioNewsLetter, please send an email to subscribe() bioseeker.com
============================================================================
8) BIOSEEKER ONLINE STORE
BioSeeker has now made it easy to order any of our products online, directly from our website. Visit www.bsg-online.biz to place an online order.
============================================================================
ADVERTISING
Do you have a message that you would like the biotech community to know? BioSeeker Group's Newsletter targets managers, scientists, venture capitalists, consultants and many more world wide. Contact us at sales .. bioseeker.com for further information on how to advertise in BSG BioNewsletter.
COURTESY
If you would like to comment on our newsletter please send us an email to feedback:_:bioseeker.com
If you would like to be removed from our newsletter list, please reply to unsubscribe[A]bioseeker.com
Received on 2002-12-11 - 01:26 GMT
This archive was generated by hypermail 2.2.0 : 2005-11-24 - 10:21 GMT